Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	5.64	0	0	0	0	0
Gross Profit	5.64	0	0	0	0	0
Selling, General & Admin	6.97	6.02	7.15	8.39	6.44	7.62
Research & Development	9.71	16.36	13.02	17.89	11.03	20.26
Other Operating Expenses	0	0	0	0	-0.67	27.88
Operating Expenses	16.68	22.38	20.16	26.28	17.47	27.88
Operating Income	-11.04	-22.38	-20.16	-26.28	-17.47	-27.88
Interest Income	0.23	0	0	0	0	0.38
Interest Expense	-1.26	0.14	0.01	0.25	0	0
Other Expense / Income	1.09	-0.27	-0.61	0.33	-2.41	-24.88
Pretax Income	-10.53	-22.25	-19.56	-26.85	-15.07	-2.63
Income Tax	1.03	-2.42	-1.8	-2.13	-1.8	-5.44
Net Income	-11.67	-19.83	-17.76	-24.73	-13.27	2.81
Shares Outstanding (Basic)	12	10	10	8	5	4
Shares Outstanding (Diluted)	12	10	10	8	5	4
Shares Change	28.15%	0.51%	21.88%	73.14%	3.85%	67.00%
EPS (Basic)	-1.09	-2.08	-1.87	-3.17	-2.95	0.65
EPS (Diluted)	-1.09	-2.08	-1.87	-3.17	-2.95	0.65
Free Cash Flow	-12.34	-17.77	-22.82	-19.88	-12.94	-15.5
Free Cash Flow Per Share	-1.01	-1.86	-2.40	-2.55	-2.87	-3.57
Gross Margin	100.00%	-	-	-	-	-
Operating Margin	-195.66%	-	-	-	-	-
Profit Margin	-206.91%	-	-	-	-	-
Free Cash Flow Margin	-218.78%	-	-	-	-	-
EBITDA	-11.17	-22.39	-20.76	-26.13	-19.81	-52.4
EBITDA Margin	-198.05%	-	-	-	-	-
Depreciation & Amortization	0.01	0.07	0.1	0.15	0.35	0.36
EBIT	-11.18	-22.45	-20.86	-26.28	-20.16	-52.76
EBIT Margin	-198.16%	-	-	-	-	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.